Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 25;24(12):2093–2106. doi: 10.1093/neuonc/noac107

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 4 — Increased expression of neoantigen leads to increased CTL activation and killing in a TCR-MHC dependent fashion. Bar plots showing relative gene expression of (A) MYRF, (D) MCM7, (G) WDR91, (J) LAMA3, (M) FAM122a to GAPDH as measured by RTqPCR for the relevant cell lines (A—U87MG; D+G—HGG2; J—HGG11, M—HGG13). Expression is represented as 2^–∆∆CT and statistical significance as calculated by paired two-tailed student t test. Activation of (B) MYRF, (E) MCM7, (H) WDR91, (K) LAMA3 and (N) FAM122a specific CTL as measured by TNFα+/CD107a+ cells by flow cytometry. All cells pregated on CD3+/CD8+ population. (C) MYRF, (F) MCM7, (I) WDR91, (L) LAMA3 and (O) FAM122a specific CTL mediated killing as measured by LDH release against primary cell lines. Data shown are from biological triplicates representative of a minimum of 3 independent experiments. Ab—W6/32 MHC class I blocking antibody. Statistical significance as calculated by 2-way ANOVA. * P < .05, ** P < .01, *** P < .001, **** P < .0001.